免疫检查点中的调节性T细胞阻断抗瘤治疗
An Zhang1, Tao Fan2, Yixiao Liu1
1Department of Colorectal Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Molecular cancer
|November 9, 2024
概括
调控性T细胞 (Tregs) 在癌症中抑制抗瘤免疫力. 向Tregs可以通过改善效应T细胞活性和优化免疫检查点阻塞疗法来提高癌症免疫疗法的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 调节性T细胞 (Tregs) 对免疫平衡至关重要,但可以阻碍抗癌免疫反应.
- 在瘤微环境中,Tregs抑制效应T细胞 (Teffs),促进癌症的进展.
- 了解Treg生物学是开发新型癌症免疫疗法的关键.
研究的目的:
- 审查Tregs在癌症发展,进展和治疗中的多方面的作用.
- 探索抑制抗瘤免疫力的Treg机制.
- 检查Treg参与和对免疫检查点阻塞 (ICB) 疗法的影响.
主要方法:
- 对Treg生物学,功能和癌症中的作用的文献综述.
- 对Treg与效应T细胞和瘤微环境相互作用的分析.
- 对Treg向疗法和ICB的生物标志物进行当前研究的综合.
主要成果:
- Tregs在癌症中表现出复杂的作用,经常通过各种机制抑制抗瘤免疫反应.
- Tregs显著影响癌症免疫疗法的疗效,包括ICB.
- 特定的Treg群体和标记可以预测ICB治疗反应.
结论:
- 准Tregs以恢复Teff活性是癌症免疫治疗的一个有希望的策略.
- 调节Treg功能可以优化ICB疗法并改善患者的治疗结果.
- 对Treg生物学和治疗向的进一步研究对于推进癌症治疗至关重要.
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
T Cell Activation and Clonal Selection
671
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
671
Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


